Ligand-receptor interactions as studied by PET: Implications for drug development

Annals of Medicine

Volumn 31, Issue 6, 1999, Pages 438-443

  Hietala, Jarmo ^a,b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b TURKU PET CENTRE   (Finland)

Author keywords

Drug development; Phase I; Positron emission tomography; Receptor; Receptor occupancy

Indexed keywords

LIGAND; RECEPTOR;

BINDING AFFINITY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; DOSE CALCULATION; DRUG DEVELOPMENT; NEUROTRANSMISSION; ONCOLOGY; PATHOPHYSIOLOGY; PHARMACODYNAMICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

EID: 0033370105     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899908998802     Document Type: Review

References (29)

1. Wong DF, Wagner HN Jr, Tune LE, Dannals RF, Pearlson GD, Links JM, et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986; 234: 1558-63.
2. 11C]raclopride. Arch Gen Psychiatry 1990; 47: 213-9.
3. Hietala J, Syvälahti E, Vuorio K, Någren K, Lehikoinen P, Ruotsalainen U, et al. Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry 1994; 51: 116-23.
4. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996; 379: 733-6.
5. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, Shea C, et al. Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci U S A 1996; 93: 14065-9.
6. 11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology (Berl) 1997; 133: 396-104.
7. Tiihonen J, Kuoppamäki M, Någren K, Bergman J, Eronen E, Syvälahti E, et al. Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography. Psychopharmacology (Berl) 1996; 126: 277-80.
8. Kanerva H, Vilkman H, Någren K, Kilkku O, Kuoppamäki M, Syvälahti E, et al. Brain 5-HT2A receptor occupancy of deramciclane in humans after a single oral administration-a positron emission tomography study. Psychopharmacology (Berl) 1999; 145: 76-81.
9. 11C]tropanyl benzilate-binding to muscarinic cholinergic receptors: methodology and kinetic modeling alternatives. J Cereb Blood Flow Metab 1994; 14: 85-99.
10. Pike VW, McCarron JA, Lammertsma AA, Osman S, Hume SP, Sargent PA, et al. Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11 C]WAY-100635. Eur J Pharmacol 1996; 301: R5-7.
11. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984; 15: 217-27.
12. 11C]raclopride binding to D2 dopamine receptors studied by PET - a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 1989; 9: 696-708.
13. 11C]raclopride in man. Synapse 1995; 20: 200-8.
14. 11C]-raclopride in vivo: a test-retest analysis. J Cereb Blood Flow Metab 1999; 19: 210-7.
15. 11C]raclopride studies. J Cereb Blood Flow Metab 1996;16: 42-52.
16. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 1997; 6: 279-87.
17. Seeman P, Guan H-C, Niznik HB. Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain. Synapse 1989; 3: 96-7.
18. 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 1993; 13: 350-6.
19. 11C-raclopride binding with continuous infusion. J Cereb Blood Flow Metab 1997; 17: 437-47.
20. Ginovart N, Farde L, Halldin C, Swahn CG. Changes in striatal D2-receptor density following chronic treatment with amphetamine as assessed with PET in nonhuman primates. Synapse 1999; 31: 154-62.
21. Laruelle M, D'Souza CD, Baldwin RM, Abi-Dargham A, Kanes SJ, Fingado CL, et al. Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 1997; 17: 162-74.
22. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 1997; 94: 2569-74.
23. Patlak CS, Pettigrew KD. A method to obtain infusion schedules for prescribed blood concentration time courses. J Appl Physiol 1976; 40: 458-63.
24. Carson RE, Channing MA, Blasberg RG, Dunn BB, Cohen RM, Rice KC, et al. Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab 1993; 13: 24-42.
25. 11C]raclopride binding. J Cereb Blood Flow Metab 1998; 18: 941-50.
26. Koepp MJ, Gunn RN, Lawrence AD, Cunningham VJ, Dagher A, Jones T, et al. Evidence for striatal dopamine release during a video game. Nature 1998; 393: 266-8.
27. 11C]NNC 756. Synapse 1999; 32: 93-109.
28. Farde L. The advantage of using positron emission tomography in drug research. Trends Neurosci 1996; 19: 211-1.
29. Grunder G, Yokoi F, Offord SJ, Ravert HT, Dannals RF, Salzmann JK, et al. Time course of 5-HT2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography. Neuropsychopharmacology 1997; 17: 175-85.